Studies have shown that markers of necroptosis (RIPK3, MLKL, and phospho-MLKL) are increased in the livers of MAFLD and MASH patients, and in mouse models of MASH [10,11,12,13,14,15]. This evidence concerns the gene MLKL and metabolic dysfunction-associated steatohepatitis.